November 05, 2013
1 min read
Save

Similar results seen with unilateral, bilateral multifocal IOL implantation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bilateral mix-and-match implantation and unilateral implantation of multifocal IOLs yielded similar visual outcomes and patient satisfaction, according to a study.

The retrospective study included 76 eyes of 53 patients; 30 patients underwent unilateral multifocal IOL implantation and 23 patients underwent bilateral mix-and-match implantation.

Patients in the bilateral implantation group received a Tecnis ZM900 diffractive multifocal IOL (Abbott Medical Optics) in one eye and a ReZoom NXG1 refractive multifocal IOL (AMO) in the other eye. Patients in the unilateral implantation group received a Tecnis ZM900 IOL in one eye.

LogMAR uncorrected distance, intermediate and near visual acuities, contrast sensitivity, patient satisfaction, spectacle independence, halo and glare were evaluated up to 1 year after surgery.

At 1 year, mean uncorrected distance visual acuity was 0.10 in the bilateral and unilateral groups. Mean uncorrected intermediate visual acuity was 0.23 in the bilateral group and 0.29 in the unilateral group. Mean uncorrected near visual acuity was 0.25 in the bilateral group and 0.27 in the unilateral group.

Patient satisfaction was slightly higher with bilateral implantation.

No significant between-group differences in contrast sensitivity or spectacle dependence were reported.

Four of 29 patients (14%) in the unilateral group reported severe halo and three of 29 patients (10%) reported severe glare. Two of 20 patients (10%) in the bilateral group reported severe halo and no patients reported severe glare. The differences were not significant.

Disclosure: The study authors have no relevant financial disclosures.